Interview with Russell Williams, President, Rx&D
You have been President of Rx&D since 2004, and have witnessed the market’s development over the years. What have been the most important issues since you started and what are…
Address: 55 Metcalfe Street Suite 1220 Ottawa Ontario K1P 6L5,Canada
Tel: 613-236-0455
Web: http://www.canadapharma.org/
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines.
Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada’s knowledge-based economy, contributing over $3 billion to the Canadian economy.
Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.
You have been President of Rx&D since 2004, and have witnessed the market’s development over the years. What have been the most important issues since you started and what are…
The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government…
The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…
Industry veteran and CEO of JSS Medical research explains what he thinks is going wrong with clinical research in Canada today, how Canadian CROs are losing out at the hands…
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing…
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for…
A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that…
The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector…
See our Cookie Privacy Policy Here
